Holen Sie sich die Stockscreener-App
10.16
5.13%
0.51
Schlusskurs vom Vortag:
$9.65
Offen:
$9.6
24-Stunden-Volumen:
74,674
Relative Volume:
0.27
Marktkapitalisierung:
$116.92M
Einnahmen:
$1.54M
Nettoeinkommen (Verlust:
$-38.70M
KGV:
-2.1756
EPS:
-4.67
Netto-Cashflow:
$-36.86M
1W Leistung:
+5.46%
1M Leistung:
-22.20%
6M Leistung:
-81.56%
1J Leistung:
-61.22%
1-Tages-Spanne:
$9.508
$10.19
1-Wochen-Bereich:
$9.11
$10.19
52-Wochen-Spanne:
$9.11
$61.90
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Firmenname
Corbus Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
617-963-0103
Adresse
500 RIVER RIDGE DRIVE, NORWOOD, MA
Vergleichen Sie CRBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
10.18 | 116.92M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.43 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
706.50 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
666.13 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.25 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.83 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Eingeleitet | Wedbush | Outperform |
| 2024-07-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-06-03 | Bestätigt | Oppenheimer | Outperform |
| 2024-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2020-09-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-03-26 | Eingeleitet | Nomura | Buy |
| 2019-04-05 | Eingeleitet | Jefferies | Buy |
| 2019-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-01-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-10-24 | Eingeleitet | B. Riley FBR | Buy |
| 2018-01-19 | Eingeleitet | Raymond James | Outperform |
| 2017-12-14 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Bestätigt | Noble Financial | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-03-30 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-11 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Chief Financial Officer Moran Sean F. was granted 27,500 shares, increasing direct ownership by 57% to 76,105 units (SEC Form 4) - Quantisnow
CRBP stock touches 52-week low at $9.26 amid market challenges - MSN
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Position Lifted by JPMorgan Chase & Co. - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Sees Significant Decline in Short Interest - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
(CRBP) Proactive Strategies - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewswire
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market - MarketWatch
Exclusive: Corbus Pharmaceuticals Reveals Strategic Vision at Elite Biotech Conference - StockTitan
CRBP stock touches 52-week low at $10.43 amid market fluctuations - Investing.com Australia
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Down 9.1% in December - MarketBeat
Short Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Decreases By 9.1% - Defense World
Brokerages Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Target Price at $62.00 - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded to Sell at StockNews.com - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $62.00 Average Price Target from Brokerages - MarketBeat
Dermatomyositis Market to Show Remarkable Growth Trends from - openPR
Corbus Pharmaceuticals Holdings, Inc. Announces Clinical Data for CRB-701 from Western Dose Escalation Study to Be Presented at ASCO GU 2025 - Marketscreener.com
Corbus Pharmaceuticals Announces that Clinical Data for - GlobeNewswire
Corbus Pharmaceuticals to Present CRB-701 Cancer Drug Trial Data at ASCO GU 2025 Symposium - StockTitan
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025 - The Manila Times
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Geode Capital Management LLC - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Sees Large Growth in Short Interest - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Update - MarketBeat
How to Take Advantage of moves in (CRBP) - Stock Traders Daily
State Street Corp Buys 153,243 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by State Street Corp - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Holdings Boosted by Fmr LLC - Defense World
Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Target Price at $62.00 - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $62.00 - MarketBeat
(CRBP) Investment Report - Stock Traders Daily
Mizuho remains bullish on Corbus stock, sees encouraging outlook for Nectin-4 ADC - Investing.com Canada
Charles Schwab Investment Management Inc. Buys 64,800 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
Charles Schwab Investment Management Inc. Boosts Stock Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Finanzdaten der Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.43%
3.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):